A Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Effect of Sinetrol on Body Composition &Metabolic Health in Peri-menopausal/Early Menopausal Women (MENOFIT)
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Effect of Sinetrol on Body Composition &Metabolic Health in Peri-menopausal/Early Menopausal Women (MENOFIT)
The menopausal transition is associated with significant hormonal and metabolic changes, primarily driven by a decline in estrogen levels. These changes contribute to alterations in body composition, including an increase in total body fat, preferential accumulation of central and visceral adipose tissue, and a reduction in lean body mass. Such redistribution of adiposity is a defining feature of peri- and early postmenopausal stages and is closely linked to increased cardiometabolic risk.
Visceral adipose tissue is metabolically active and contributes to the development of insulin resistance, dyslipidemia, and chronic low-grade inflammation through the secretion of pro-inflammatory cytokines and adipokines.These metabolic alterations may adversely impact overall health, physical function, and quality of life in peri- and postmenopausal women. In addition, menopause-associated changes in energy expenditure and appetite regulation may further predispose individuals to weight gain and fat accumulation.
Conventional management strategies for weight gain during menopause include lifestyle interventions such as dietary modification and physical activity; however, long-term adherence to these approaches is often limited. Pharmacological options may also be associated with safety concerns or may not directly address body composition changes. Therefore, there is increasing interest in nutraceutical approaches that may safely support metabolic health and body composition in this population.6 Sinetrol XPur C is a standardized polyphenolic extract derived from citrus fruits, including red orange, grapefruit, and sweet orange, enriched with flavonoids such as naringin and hesperidin. These bioactive compounds have been shown to influence lipid metabolism and adipocyte function.
Clinical studies have demonstrated the potential of Sinetrol XPur C in supporting body composition management.
The available clinical evidence suggests that Sinetrol XPur C may support body composition and metabolic health through mechanisms involving enhanced lipolysis, improved energy metabolism, and modulation of adipose tissue function.
Given the physiological changes associated with menopause and the need for safe and effective interventions, Sinetrol XPur C may represent a promising nutritional approach for improving body composition and related metabolic parameters in peri- and early postmenopausal women.
The study objective is to assess the effect of Sinetrol XPur C on Body composition (Total fat mass and fat free mass) using Dual-Energy- X-ray Absorptiometry (DEXA) when compared to baseline and placebo.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- perimenopausal or early menopausal women
Exclusion Criteria:
- women under HRT treatment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: placebo
maltodekstrin
|
dietary supplementation
|
|
Aktiv komparator: investigational product
Sinetrol 630 mg/capsule/day
|
dietary supplementation
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Body composition (Total fat mass and fat free mass) when compared to baseline and placebo.
Tidsramme: 180 days
|
To assess the effect of Sinetrol XPur C on Body composition (Total fat mass and fat free mass) using Dual-Energy- X-ray Absorptiometry (DEXA) when compared to baseline and placebo.
|
180 days
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- MENOFIT
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .